CLAIMS

1. A compound of Formula I:



Formula I

or a pharmaceutically acceptable salt, hydrate, polymorph, solvate, prodrug, enantiomer, or stereoisomer thereof, wherein;

~~Wherein,~~

R^1~~,~~ and R^3 each independently represent~~s CH_3CO-, acetyl, D, H, CD_3CO-~~ -$COCH_3$,




,

,

,

,

,

,

,

,

,

,

,

or

;

R^2, and R^4 each independently represents H, D,


,

,


,

,

,

,

,

,

,

,

,

,

,

,


O
O

,


O
HO
OH
OH

,


N
H
H2N
O
OH

,


O
O
NH2
HO

,


NH2
OH
O

,


O
O
4
7
10
13
16
19

,


O
O
5
8
11
14
17
20

,


O
5
8
11
14
17
20

,


4
7
10
13
16
19
O

,


H
OH
HO
H
N
O
O

,


N
CH3
HO
OH
N
H

,


O
OH
O
HN
O

,


O
HO
OH
HO
HN

,


NHCOCH3
O

,


O
OH

,


CO2H
O

,


O
OCOCH3

,


CONH2
O

,


O
O
CH3
CH3
H3C
O
CH3
CH3
6 - 10

,


O
O
OH
O

,


,

,

,

,

,

,

,

,

,



,


,



or


;

a is ~~independently~~ 2, 3 or 7;

each b is independently 3, 5 or 6;

e is ~~independently~~ 1, 2 or 6; and

c and d are each independently H, D, -OH, -OD, C_1-C_6-alkyl, $-NH_2$ or $-COCH_3$.

2. A compound of Formula II:



Formula II

or a pharmaceutically acceptable salt, hydrate, polymorph, solvate, prodrug, enantiomer, or stereoisomer thereof, wherein;

~~Wherein~~

R^1, and R^3 each independently represent~~s~~ H, D,




or

;

R^2, and R^4 each independently represent~~s~~ D, CH_3CO, CD_3CO,


,

,

,

,

,

,

,

,


O
H3C
O
O
H2
C
O
,

O
HO
OH
OH
,


HS
H
N
O
O
O
,

H3C
O
O
O
O
,


O
HO
O
O
NH2
,

N
H
O
H2N
OH
,


O
O
HO
NH2
,

NH2
OH
O
,


O
O
4
7
10
13
16
19
,


O
O
5
8
11
14
17
20
,


O
5
8
11
14
17
20

,


O
4
7
10
13
16
19

,


H
OH
HO
H
N
O
O

,


N
CH3
HO
OH
N
H

,


O
OH
O
HN
O

,


O
HO
OH
HO
HN

,


NHCOCH3
O

,


O
OH

,


CO2H
O

,


O
OCOCH3

,


CONH2
O

,


O
O
CH3
H3C
O
CH3
CH3
CH3
6 - 10

,


O
O
OH
O

,














,


,


,


,


or


;

a is ~~independently~~ 2, 3 or 7;

each b is independently 3, 5 or 6;

e is ~~independently~~ 1, 2 or 6; and

c and d are each independently H, D, -OH, -OD, C_1-C_6-alkyl, -NH_2 or -$COCH_3$.

3. A ~~P~~pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.
4. A ~~P~~pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier.

~~5. The pharmaceutical composition of claim 3, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup, topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.~~

~~6. The pharmaceutical composition of claim 4, which is formulated to treat the underlying etiology with an effective amount administering the patient in need by oral administration, delayed release or sustained release, transmucosal, syrup,~~

~~topical, parenteral administration, injection, subdermal, oral solution, rectal administration, buccal administration or transdermal administration.~~

~~7.~~5. Compounds and compositions of claim 3~~5~~, ~~are formulated~~ for use in the treatment of gastrointestinal diseases and inflammation such as inflammatory bowel disease, ulcerative colitis, mild-to-moderate Crohn's disease, rheumatoid arthritis, inflammatory arthritis, psoriatic arthritis, liver cirrhosis and idiopathic urticaria.

~~8.~~6. Compounds and compositions of claim 4~~6~~, ~~are formulated~~ for use in the treatment of gastrointestinal diseases and inflammation such as inflammatory bowel disease, ulcerative colitis, mild-to-moderate Crohn's disease, rheumatoid arthritis, inflammatory arthritis, psoriatic arthritis, liver cirrhosis and idiopathic urticaria.

~~9.~~7. A pharmaceutical composition of claim 3, further comprising a molecular conjugate of mesalazine, ~~eicosapentaenoic acid and~~ caprylic acid and carboxylic compounds selected from a group consisting of eicosapentaenoic acid and docosahexaenoic acid.

8. The molecular conjugate of claim 7, wherein the carboxylic acid compound is eicosapentaenoic acid.

9. The molecular conjugate of claim 7, wherein the carboxylic acid compound is docosahexaenoic acid.

10. A pharmaceutical composition of claim 4, further comprising a molecular conjugate of sulfasalazine, ~~eicosapentaenoic acid and~~ caprylic acid and a compound selected from a group consisting of eicosapentaenoic acid and docosahexaenoic acid.

11. ~~A pharmaceutical composition comprising a~~ The molecular conjugate of claim 10, ~~mesalazine, docosahexaenoic acid and caprylic~~ wherein the carboxylic acid compound is eicosapentaenoic acid.

12. ~~A pharmaceutical composition comprising a~~ The molecular conjugate of claim 10, ~~sulfasalazine,~~ wherein the carboxylic acid compound is docosahexaenoic acid ~~and caprylic acid~~.